0IGA Stock Chart & Stats
$7.42
-$0.18(-2.43%)
At close: 4:00 PM EDT
$7.42
-$0.18(-2.43%)
Day’s Range― - ―
52-Week Range$4.37 - $13.91
Previous CloseN/A
Volume199.00
Average Volume (3M)1.16K
Market Cap
$289.18M
Enterprise Value$879.71
Total Cash (Recent Filing)$139.70M
Total Debt (Recent Filing)$581.80M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Nov 11, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.44
Shares Outstanding51,273,335
10 Day Avg. Volume770
30 Day Avg. Volume1,163
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)1.27
Price to Sales (P/S)0.89
P/FCF Ratio4.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside34.77% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)0.36
Revenue Forecast (FY)$655.55M
Bulls Say, Bears Say
Bulls Say
Biodefense Market PositionLarge U.S. government awards and international approvals reinforce Emergent’s role in biodefense preparedness. This specialized portfolio and established supply relationships can support recurring demand as governments maintain and replenish strategic medical countermeasure stockpiles.
Margin And Cash ImprovementHigher adjusted EBITDA, stronger gross margins and positive operating cash flow indicate improved operating execution and cash conversion. Sustaining these gains would give Emergent greater capacity to fund operations, service debt and invest in its specialty products.
Cost Structure And Liquidity ActionsThe restructuring addresses excess costs through workforce and facility reductions, while refinancing extends debt maturities and lowers rates. If executed effectively, these actions can improve recurring margins, reduce financing pressure and provide more flexibility for the turnaround.
Bears Say
Naloxone CompetitionNew OTC and prescription competitors create a structural threat to NARCAN’s commercial volumes and pricing. Ongoing erosion in this business could reduce a key revenue and cash contribution, making Emergent more dependent on government contracts and other specialty products.
Unstable ProfitabilityThe renewed net loss and major impairment show that improved adjusted operating results are not yet translating into dependable GAAP earnings. Volatile profitability can constrain reinvestment, weaken equity and increase reliance on restructuring or financing actions.
Leverage And Revenue DependenceElevated leverage reduces financial flexibility while the guidance cut highlights dependence on uncertain contract timing and pressured naloxone sales. Lower revenue and EBITDA could make debt reduction harder and increase sensitivity to procurement delays or further competition.
Emergent Biosolutions News
0IGA FAQ
What was Emergent Biosolutions’s price range in the past 12 months?
Emergent Biosolutions lowest share price was $4.37 and its highest was $13.90 in the past 12 months.
What is Emergent Biosolutions’s market cap?
Emergent Biosolutions’s market cap is $289.18M.
When is Emergent Biosolutions’s upcoming earnings report date?
Emergent Biosolutions’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Emergent Biosolutions’s earnings last quarter?
Emergent Biosolutions released its earnings results on Aug 05, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of -$0.085 by $0.685.
Is Emergent Biosolutions overvalued?
According to Wall Street analysts Emergent Biosolutions’s price is currently Undervalued.
Does Emergent Biosolutions pay dividends?
Emergent Biosolutions does not currently pay dividends.
What is Emergent Biosolutions’s EPS estimate?
Emergent Biosolutions’s EPS estimate is -0.39.
How many shares outstanding does Emergent Biosolutions have?
Emergent Biosolutions has 51,273,335 shares outstanding.
What happened to Emergent Biosolutions’s price movement after its last earnings report?
Emergent Biosolutions reported an EPS of $0.6 in its last earnings report, beating expectations of -$0.085. Following the earnings report the stock price went down -31.621%.
Which hedge fund is a major shareholder of Emergent Biosolutions?
Currently, no hedge funds are holding shares in GB:0IGA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emergent Biosolutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (34.77% Upside)
$10.00 (34.77% Upside)
Blogger Sentiment
Neutral
GB:0IGA Sentiment 50%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.19%
Trailing 12-Months
Company Description
Emergent Biosolutions
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
0IGA Company Deck
0IGA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a balance of strong near-term operational execution and financial results—Q2 revenue and adjusted EBITDA materially exceeded expectations, driven by accelerated MCM deliveries and improved margins—alongside significant commercial headwinds in the naloxone business that prompted a $191M noncash impairment and a downward revision to full-year revenue and profitability guidance. Management is taking proactive restructuring and capital allocation actions (debt refinancing, share repurchases, $40M annualized cost-savings plan) to preserve liquidity and position the company for 2027, but the naloxone competitive dynamics and guidance cuts temper the otherwise strong quarter.View all GB:0IGA earnings summaries0IGA Stock 12 Month Forecast
Average Price Target
$10.00
▲(34.77% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―